CING Cingulate Inc.
Cingulate Inc. (CING) is expected to report earnings on November 12, 2026, before the market open. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.6% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Cingulate Inc.
Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
Sector
Healthcare
Industry
Biotechnology